4-((((Benzyloxy)carbonyl)amino)methyl)-1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid, 98%, 100mg

Acetyl-4-iodo-DL-phenylalanine, 97.0%, 1g

N-?[(11bS)?-?2,?6-?Bis[3,?5-?bis(trifluoromethyl)?phenyl]?-?4-?oxido-dinaphtho[2,?1-?d:1',?2'-?f]?[1,?3,?2]?dioxaphosphepin-?4-?yl]?-?1,?1,?1-?trifluoromethanesulfonamide, 97%, 250mg

Methyl(2R,7aR)-2-(benzyloxy)tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate, 100mg

Infinity corrected plan PL-M 10x/0.25 IOS objective. Working distance 12.2 mm

1,3,5-Tris(pyrazol-4-yl)benzene, 95%, 100mg

(6-Bromonaphthalen-2-yl)boronic acid, 98%, 500mg

(2E)-1-{[1,1'-biphenyl]-4-yl}-3-(2,3-dimethoxyphenyl)prop-2-en-1-one, 95.0%, 2g

3,5-Diphenyl-1-(o-tolyl)formazan>92.0%(HPLC)100mg

2-(Methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)acetohydrazide, 98%, 50mg

2-Amino-6-methylisonicotinic acid, 95.0%, 1g

Methyl 3-amino-6-chloropyrazine-2-carboxylate, 95.0%, 1g

2-(Bromomethyl)-6-(trifluoromethyl)pyridine, 95.0%, 250mg